Side-by-side comparison
Amgen vs Gilead Sciences
As of Sep 25, 2026, P/S is 5.9x for Amgen vs 6.1x for Gilead Sciences; revenue growth is 9.1% for Amgen vs 5.5% for Gilead Sciences; operating margin is 30.0% for Amgen vs -8.2% for Gilead Sciences; net margin is 23.0% for Amgen vs -10.6% for Gilead Sciences.
Key metrics
| Metric | AMGN | GILD |
|---|---|---|
| Price | $414.61 | $150.93 |
| Market cap | $224.15B | $187.15B |
| P/E | 25.8x (#1) | — |
| P/S | 5.9x (#1) | 6.1x (#2) |
| Revenue growth | 9.1% (#1) | 5.5% (#2) |
| Operating margin | 30.0% (#1) | -8.2% (#2) |
| Net margin | 23.0% (#1) | -10.6% (#2) |
| Debt / equity | 4.44 (#2) | 2.01 (#1) |
| 1-year return | +51.9% (#1) | +34.6% (#2) |
| Research score | 67/100 (#1) | 42/100 (#2) |
Higher is better for growth, margins, one-year return and overall score; lower is better for valuation and debt ratios. Ties share a rank and missing values are excluded.
Company research
- Amgen Inc. (AMGN) — Drug Manufacturers—General
- Gilead Sciences, Inc. (GILD) — Drug Manufacturers—General